Skip to main content
S&P 5007,591.70-0.58%DOW52,064.10-0.60%NASDAQ26,081.72-0.65%BTC$76,799.00-1.71%ETH$2,453.65-0.48%GOLD$4,367.20-0.91%OIL$103.26+0.76%
Smart Investors Daily
KR

NASDAQ · KRRO

Korro Bio, Inc.

Healthcare · Biotechnology

$13.06

Up+$0.13 (+1.01%)

Updated Sep 11, 2026, 4:07 AM

SID Score

4.5/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
74.09M
P/E ratio
-0.81
Dividend yield
0.00%
52-week range
$9.12 – $15.56
Volume
145.8K
Avg. volume
526.07K

Price performance

KRRO price history

1M range · 20 trading sessions · Daily adjusted prices

KRRO closed at $13.06 after 20 trading sessions, down 1.73% for the selected period.

Last close
$13.06
Period change
-1.73%
Period low
$11.62
Period high
$13.95
Daily close
View OHLC price history
KRRO OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 10, 2026$12.80$13.16$12.38$13.06145.8K
Sep 9, 2026$13.44$13.76$12.87$12.93131.5K
Sep 8, 2026$12.03$13.62$11.89$13.51119.12K
Sep 4, 2026$11.53$12.30$11.53$12.2478.43K
Sep 3, 2026$12.09$12.6275$11.30$11.6282.73K
Sep 2, 2026$12.26$12.78$11.82$11.9781.07K
Sep 1, 2026$12.57$12.635$12.14$12.2459.01K
Aug 31, 2026$12.78$13.04$12.28$12.4987.96K
Aug 28, 2026$13.13$13.5488$12.80$12.9167.37K
Aug 27, 2026$13.62$13.69$13.235$13.2648.57K
Aug 26, 2026$13.71$13.98$13.23$13.6841.28K
Aug 25, 2026$13.14$13.90$13.14$13.7379.71K
Aug 24, 2026$13.18$13.5969$12.66$13.0770.37K
Aug 21, 2026$13.02$13.56$13.02$13.1845.71K
Aug 20, 2026$13.77$13.77$12.83$12.9664.12K
Aug 19, 2026$13.50$14.185$13.50$13.95140.97K
Aug 18, 2026$13.03$13.255$12.63$13.2270.6K
Aug 17, 2026$13.11$13.72$12.8755$13.1478.58K
Aug 14, 2026$13.34$13.34$12.72$13.2847.07K
Aug 13, 2026$13.39$13.93$12.89$13.29113.83K

Latest KRRO news

The latest Smart Investors Daily articles mentioning KRRO.

Stock researchCompany · Overview

KRRO research

Overview

Company profile and research snapshot.

Company profile

Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Hold
Average target
$91.25
Implied upside
—
Analysts
16
KRRO recent ratings
DateFirmRatingTarget
Aug 20, 2026HC Wainwright & Co.Buy—
May 19, 2026HC Wainwright & Co.Buy—
May 18, 2026CitigroupBuy—
Mar 13, 2026Cantor FitzgeraldOverweight—
Mar 13, 2026Raymond JamesOutperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Aug 27, 2026

Korro to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Korro, Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company leveraging a novel oligonucleotide promoted editing of RNA (OPERA®) platform to develop a new class of genetic medicines for rare and highly prevalent diseases, today announced that Ram Aiyar, President & Chief Executive Officer will participate in the following investor conferences: Citi 2026 Biopharma Back to School SummitFormat: Fireside chat moderated by Yigal Nochomovitz,

Benzinga · Aug 6, 2026

Korro Bio Q2 EPS $(1.07) Beats $(1.31) Estimate

Korro Bio (NASDAQ:KRRO) reported quarterly losses of $(1.07) per share which beat the analyst consensus estimate of $(1.31) by 18.32 percent. This is a 60.95 percent increase over losses of $(2.74) per share from the

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By